Brief: Solid Biosciences Announces Licensing Agreement With Andelyn Biosciences For The Use Of Proprietary Next-Generation Capsid Aav-Slb101
17/11/2025 13:12
Solid Biosciences Inc SLDB.O: SOLID BIOSCIENCES ANNOUNCES LICENSING AGREEMENT WITH ANDELYN BIOSCIENCES FOR THE USE OF PROPRIETARY NEXT-GENERATION CAPSID AAV-SLB101 SOLID BIOSCIENCES INC - GRANTS ANDELYN LICENSE TO UTILIZE AAV-SLB101 SOLID BIOSCIENCES INC - AAV-SLB101 WELL TOLERATED IN 23 PARTICIPANTS IN CLINICAL TRIAL Source text: ID:nGNXDGf4N Further company coverage: SLDB.O
Recent news on Solid Biosciences
See all newsMarketing Agreement To Advance Gene Therapy Delivery And Analytics
Solid Biosciences Q1 net loss widens on higher R&D costs
Solid Biosciences Q4 net loss widens on higher R&D costs
NASDAQ RESUMED AT 01:58 PM
Brief: Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial